Aiforia Technologies has announced the launch of a new clinical AI solution for gastric cancer diagnostics. This solution is CE-IVD marked under the IVDR.
Aiforia Gastric Cancer AI application is designed to support pathologists in the detection and reporting of gastric cancer in digitised gastric tissue samples.
Gastric cancer is one of the leading causes of cancer-related deaths worldwide. Detecting cancer in gastric biopsies can be difficult, as tumour areas may be very small, scattered, or visually subtle. Certain forms of gastric cancer are especially challenging to identify and can be easy to miss during routine review. Aiforia Gastric Cancer solution is designed to support a high-sensitivity diagnostic approach, helping pathologists focus their attention on suspicious areas and reducing the risk that cancerous regions go unnoticed. The AI solution supports detection across all major types of gastric cancer, including hard-to-identify forms, where tumour cells can be sparse and difficult to see.
Aiforia Gastric Cancer AI solution is built on Aiforia’s Foundation Engine technology, developed to perform robustly across real-world variation in sample quality, staining, and scanning. The solution integrates seamlessly into existing digital pathology workflows through the Aiforia Clinical Suite Viewer, which supports the full case review and reporting in the same user interface.
“Healthcare systems are under increasing pressure to deliver accurate diagnostics with limited resources. Aiforia Gastric Cancer solution is designed to help hospitals improve diagnostic efficiency, reduce the risk of missed cancers, and support consistent performance at scale - all while fitting seamlessly into existing digital pathology workflows. This latest release further strengthens Aiforia's broad portfolio of CE-IVD marked AI models, cementing our position as a market leader in the field of AI-driven digital pathology,” says Jukka Tapaninen, CEO of Aiforia.